Last reviewed · How we verify
Standard Antibiotics treatment duration
Standard antibiotics target and kill bacteria by inhibiting their cell wall synthesis or interfering with their protein synthesis.
Standard antibiotics target and kill bacteria by inhibiting their cell wall synthesis or interfering with their protein synthesis. Used for Community-acquired pneumonia, Skin and soft tissue infections.
At a glance
| Generic name | Standard Antibiotics treatment duration |
|---|---|
| Sponsor | University of Oxford |
| Drug class | Beta-lactam antibiotic |
| Target | Penicillin-binding proteins |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
This is achieved through various mechanisms, including inhibiting cell wall synthesis by targeting enzymes such as penicillin-binding proteins, or interfering with protein synthesis by binding to ribosomes. This ultimately leads to the death of the bacterial cell.
Approved indications
- Community-acquired pneumonia
- Skin and soft tissue infections
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Allergic reactions
Key clinical trials
- Intracalvariosseous Plus Intravenous Antibiotics for Moderate-to-Severe Bacterial Meningitis (NA)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- The Impact of Fast Antimicrobial Sensitivity Testing Tools on Stewardship Antibiotic and Clinical Outcome (ACT-FAST) (NA)
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- FuKe Qianjin Capsule Plus Antibiotics for Chronic Endometritis (PHASE4)
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Dual-light Antibacterial Photodynamic Therapy as an Adjunctive Treatment to Corticosteroid Treatment in OLP (NA)
- An Adaptive Multi-arm Trial to Improve Clinical Outcomes Among Children Recovering From Complicated SAM (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard Antibiotics treatment duration CI brief — competitive landscape report
- Standard Antibiotics treatment duration updates RSS · CI watch RSS
- University of Oxford portfolio CI